Form 4 for FENC FENNEC PHARMACEUTICALS INC.
Accepted 2024-04-18 00:00:00 ET · period of report 2024-04-17 · accession 0001415889-24-011190 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-04-18 | 2024-04-17+ | FENC | Haigh Adrian | COO | S - Sale | $6.04 | 0 | 44.4K | New | $0 |
| DM | 2024-04-18 | 2024-04-17+ | FENC | Haigh Adrian | COO | M - OptEx | $2.31 | -44.4K | 426.9K | -9% | -$102.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-04-17 | S | A | 22,222 | $2.31 | 22,222 | D | — | — | (F1) Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. |
| 2 | Common | Common Shares | 2024-04-18 | S | D | 22,222 | $9.62 | 0 | D | — | — | (F4) Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023. |
| 3 | Common | Common Shares | 2024-04-17 | S | D | 22,222 | $9.91 | 22,222 | D | — | — | (F3) Shares disposed pursuant to a 10b5-1 plan dated August 17, 2023. |
| 4 | Common | Common Shares | 2024-04-18 | S | A | 22,222 | $2.31 | 44,444 | D | — | — | (F2) Shares acquired pursuant to an option exercise pursuant to a 10b5-1 plan dated August 17, 2023. |
| 5 | Derivative | Common Shares | 2024-04-17 | M | D | 22,222 | $2.31 | 449,135 | D | $2.31 · 2014-04-25 to 2024-04-25 | 22,222 Options | (F5) Option exercise made pursuant to a 10b5-1 plan dated August 17, 2023. |
| 6 | Derivative | Common Shares | 2024-04-18 | M | D | 22,222 | $2.31 | 426,913 | D | $2.31 · 2014-04-25 to 2024-04-25 | 22,222 Options | (F6) Option exercise made pursuant to a 10b5-1 plan dated August 17, 2023. |